X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4378) 4378
tetrazoles - therapeutic use (4281) 4281
male (3426) 3426
female (2535) 2535
middle aged (2011) 2011
hypertension - drug therapy (1903) 1903
antihypertensive agents - therapeutic use (1841) 1841
animals (1734) 1734
aged (1716) 1716
tetrazoles - pharmacology (1562) 1562
angiotensin ii type 1 receptor blockers - therapeutic use (1344) 1344
valsartan (1332) 1332
treatment outcome (1280) 1280
hypertension (1252) 1252
blood pressure - drug effects (1233) 1233
valine - analogs & derivatives (1161) 1161
pharmacology & pharmacy (1153) 1153
biphenyl compounds - therapeutic use (1112) 1112
benzimidazoles - therapeutic use (1099) 1099
adult (1060) 1060
peripheral vascular disease (1014) 1014
rats (984) 984
valine - therapeutic use (949) 949
tetrazoles - administration & dosage (928) 928
tetrazoles - adverse effects (905) 905
drug therapy, combination (882) 882
cardiac & cardiovascular systems (857) 857
double-blind method (818) 818
angiotensin receptor antagonists (790) 790
imidazoles - therapeutic use (785) 785
angiotensin-converting enzyme inhibitors - therapeutic use (703) 703
heart failure - drug therapy (668) 668
hypertension - physiopathology (667) 667
losartan (599) 599
angiotensin (561) 561
dose-response relationship, drug (517) 517
time factors (509) 509
blood pressure (502) 502
prospective studies (497) 497
heart failure (493) 493
blood-pressure (486) 486
antihypertensive agents - adverse effects (470) 470
mortality (464) 464
antihypertensive agents - administration & dosage (450) 450
drug therapy (449) 449
antihypertensive agents - pharmacology (447) 447
angiotensin ii type 1 receptor blockers - pharmacology (431) 431
irbesartan (430) 430
risk factors (425) 425
cilostazol (413) 413
candesartan (404) 404
hypertension - complications (400) 400
mice (381) 381
randomized controlled trials as topic (381) 381
aged, 80 and over (376) 376
biphenyl compounds - pharmacology (374) 374
medicine, general & internal (370) 370
disease models, animal (361) 361
amlodipine - therapeutic use (355) 355
benzimidazoles - pharmacology (355) 355
imidazoles - pharmacology (343) 343
analysis (332) 332
double-blind (332) 332
renin-angiotensin system - drug effects (331) 331
follow-up studies (329) 329
rats, sprague-dawley (329) 329
angiotensin receptor antagonists - therapeutic use (324) 324
platelet aggregation inhibitors - therapeutic use (323) 323
hydrochlorothiazide - therapeutic use (320) 320
tetrazoles (318) 318
angiotensin ii type 1 receptor blockers - adverse effects (299) 299
therapy (294) 294
tetrazoles - pharmacokinetics (289) 289
medicine & public health (285) 285
research (284) 284
risk (284) 284
angiotensin ii (283) 283
care and treatment (281) 281
internal medicine (276) 276
prevention (275) 275
valine - pharmacology (273) 273
expression (272) 272
aminobutyrates - therapeutic use (271) 271
olmesartan medoxomil (271) 271
renin-angiotensin system (267) 267
amlodipine (266) 266
heart failure - physiopathology (263) 263
calcium channel blockers - therapeutic use (260) 260
angiotensin ii type 1 receptor blockers - administration & dosage (251) 251
clinical trials as topic (250) 250
drug combinations (249) 249
diabetes (246) 246
biphenyl compounds - adverse effects (243) 243
losartan - therapeutic use (241) 241
disease (239) 239
rats, wistar (239) 239
heart-failure (236) 236
imidazoles - adverse effects (231) 231
urology & nephrology (231) 231
efficacy (229) 229
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5450) 5450
Japanese (157) 157
German (144) 144
Chinese (63) 63
Russian (48) 48
French (36) 36
Spanish (28) 28
Italian (14) 14
Czech (9) 9
Hungarian (7) 7
Ukrainian (6) 6
Swedish (5) 5
Dutch (3) 3
Danish (2) 2
Finnish (2) 2
Polish (2) 2
Portuguese (2) 2
Arabic (1) 1
Bulgarian (1) 1
Hebrew (1) 1
Norwegian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Postgraduate Medical Journal, ISSN 0032-5473, 12/2016, Volume 92, Issue 1094, pp. 726 - 734
An estimated 5.1 million Americans have chronic heart failure and this is expected to increase 25% by 2030. Heart failure is a clinical syndrome that evolves... 
MEDICINE, GENERAL & INTERNAL | INHIBITION | METAANALYSIS | RANDOMIZED-TRIAL | IN-HOSPITAL MORTALITY | DYSFUNCTION | NATRIURETIC PEPTIDE | COMBINATION | EPIDEMIOLOGY | ROSUVASTATIN | URODILATIN | Vasodilator Agents - therapeutic use | Erythropoietin - therapeutic use | United States | Humans | Calcium Channel Blockers - therapeutic use | Heart Failure - physiopathology | Aminobutyrates - therapeutic use | Cardiotonic Agents - therapeutic use | Societies, Medical | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Isosorbide Dinitrate - therapeutic use | Cardiology | Platelet Aggregation Inhibitors - therapeutic use | Digoxin - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Hematinics - therapeutic use | Fumarates - therapeutic use | Anticoagulants - therapeutic use | Amides - therapeutic use | Antihypertensive Agents - therapeutic use | Evidence-Based Medicine | Heart Failure - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | American Heart Association | Stroke Volume | Cardiovascular Agents - therapeutic use | Hydralazine - therapeutic use | Atrial Natriuretic Factor - therapeutic use | Iron - therapeutic use | Benzazepines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Diuretics - therapeutic use | Tetrazoles - therapeutic use | Peptide Fragments - therapeutic use | Angiotensin Receptor Antagonists - therapeutic use | Drug Combinations | Practice Guidelines as Topic | Heart failure | Care and treatment | Usage | Analysis | Americans | Diagnosis | Cardiac output | Health aspects | Evidence-based medicine
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 2015, Volume 131, Issue 17, pp. 1486 - 1494
Background Our aim was to describe the incidence and predictors of stroke in patients who have heart failure without atrial fibrillation (AF). Methods and... 
Heart failure | Stroke | Sinus rhythm | Atrial fibrillation | Risk factors | Ventricular ejection fraction | heart failure | risk factors | CARDIAC & CARDIOVASCULAR SYSTEMS | VENTRICULAR SYSTOLIC FUNCTION | RANDOMIZED-TRIAL | NATRIURETIC PEPTIDE | stroke | ASPIRIN | atrial fibrillation | CONVERTING-ENZYME INHIBITORS | THERAPY | WARFARIN | EJECTION FRACTION | ventricular ejection fraction | sinus rhythm | PERIPHERAL VASCULAR DISEASE | CANDESARTAN | THROMBOEMBOLISM | Follow-Up Studies | Humans | Middle Aged | Male | Diabetes Mellitus, Type 1 - complications | Peptide Fragments - blood | Aged, 80 and over | Adult | Female | Stroke - epidemiology | Natriuretic Peptide, Brain - blood | Benzimidazoles - therapeutic use | Heart Failure - complications | Stroke - prevention & control | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Rosuvastatin Calcium | Biomarkers - blood | Heart Failure - drug therapy | Randomized Controlled Trials as Topic | Stroke Volume | Cardiovascular Agents - therapeutic use | Stroke - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Atrial Fibrillation - etiology | Fatty Acids, Omega-3 - therapeutic use | Tetrazoles - therapeutic use | Aged | Fluorobenzenes - therapeutic use | Fatty Acids | Peptide Fragments/ blood | Omega-3/ therapeutic use | Tetrazoles/therapeutic use | Sulfonamides/ therapeutic use | Kardiologi | 80 and over | Biological Markers/blood | Natriuretic Peptide | Pyrimidines/ therapeutic use | Cardiovascular Agents/therapeutic use | Stroke/epidemiology/ etiology/prevention & control | Benzimidazoles/therapeutic use | Diabetes Mellitus | Type 1/complications | Brain/ blood | Cardiac and Cardiovascular Systems | Atrial Fibrillation/etiology | Fluorobenzenes/ therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors/ therapeutic use | Heart Failure/complications/ drug therapy
Journal Article
Circulation. Heart failure, ISSN 1941-3297, 2017, Volume 10, Issue 10
BACKGROUND: Patients with heart failure (HF) and atrial fibrillation (AF) have higher circulating levels of NT-proBNP (N-terminal pro-B-type natriuretic... 
heart failure | natriuretic peptide, brain | atrial fibrillation | TRIAL | NEPRILYSIN | CARDIAC & CARDIOVASCULAR SYSTEMS | INHIBITION | ALISKIREN | ENALAPRIL | Prognosis | Humans | Middle Aged | Heart Failure - physiopathology | Hospitalization - statistics & numerical data | Male | Heart Failure - blood | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Case-Control Studies | Peptide Fragments - blood | Cardiovascular Diseases - mortality | Female | Natriuretic Peptide, Brain - blood | Heart Failure - complications | Fumarates - therapeutic use | Atrial Fibrillation - complications | Amides - therapeutic use | Antihypertensive Agents - therapeutic use | Heart Failure - drug therapy | Atrial Fibrillation - blood | Stroke Volume | Tetrazoles - therapeutic use | Aged | Angiotensin Receptor Antagonists - therapeutic use | Cohort Studies | Cardiovascular Diseases/mortality | Atrial Fibrillation/blood/complications | Amides/therapeutic use | Klinisk medicin | Tetrazoles/therapeutic use | Fumarates/therapeutic use | Aminobutyrates/therapeutic use | Hospitalization/statistics & numerical data | Angiotensin Receptor Antagonists/therapeutic use | Heart Failure/blood/complications/drug therapy/physiopathology | Natriuretic Peptide | Antihypertensive Agents/therapeutic use | Enalapril/therapeutic use | Brain/blood | Clinical Medicine | Peptide Fragments/blood
Journal Article
European Journal of Heart Failure, ISSN 1388-9842, 08/2005, Volume 7, Issue 5, pp. 710 - 721
...‐being and prolong life. This may be due to unfamiliarity with the evidence‐base for these therapies, the clinical guidelines recommending the use of these treatments or both, as well as concerns regarding adverse events... 
Heart failure | Isosorbide dinitrate | Beta‐blockers | Digoxin | Angiotensin receptor blockers | Pharmacology | Aldosterone antagonists | Treatment | Eplerenone | Spironolactone | Hydralazine | ACE inhibitors | Clinical recommendations | Beta-blockers | VENTRICULAR SYSTOLIC DYSFUNCTION | heart failure | treatment | CARDIAC & CARDIOVASCULAR SYSTEMS | angiotensin receptor blockers | QUALITY-OF-CARE | hydralazine | eplerenone | isosorbide dinitrate | RANDOMIZED INTERVENTION TRIAL | beta-blockers | MEDICAL-TREATMENT | GENERAL-PRACTICE | digoxin | spironolactone | CONVERTING-ENZYME-INHIBITORS | clinical recommendations | CARDIAC-INSUFFICIENCY | pharmacology | NATIONAL-SURVEY | aldosterone antagonists | ELDERLY-PATIENTS | Benzopyrans - therapeutic use | Valsartan | Angiotensin Receptor Antagonists | Bisoprolol - therapeutic use | Humans | Carbazoles - administration & dosage | Heart Failure - physiopathology | Valine - administration & dosage | Enalapril - therapeutic use | Ethanolamines - administration & dosage | Indoles - administration & dosage | Ramipril - administration & dosage | Captopril - therapeutic use | Propanolamines - therapeutic use | Lisinopril - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Ramipril - therapeutic use | Drug Therapy, Combination | Enalapril - administration & dosage | Spironolactone - therapeutic use | Adrenergic beta-Antagonists - administration & dosage | Adrenergic beta-Antagonists - therapeutic use | Benzimidazoles - therapeutic use | Lisinopril - administration & dosage | Nebivolol | Valine - analogs & derivatives | Metoprolol - therapeutic use | Metoprolol - administration & dosage | Evidence-Based Medicine | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Bisoprolol - administration & dosage | Heart Failure - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | Stroke Volume | Benzopyrans - administration & dosage | Captopril - administration & dosage | Guideline Adherence | Ethanolamines - therapeutic use | Indoles - therapeutic use | Metoprolol - analogs & derivatives | Tetrazoles - therapeutic use | Valine - therapeutic use | Carbazoles - therapeutic use | Propanolamines - administration & dosage | Practice Guidelines as Topic | Prescription writing | Corticosteroids | Isosorbide mononitrate | Family medicine | Nitrates | Peptide hormones | Aldosterone | Preventive health services | Cardiac patients | Angiotensin | Antiandrogens | Medicine, Preventive | Steroids | Kardiologi | converting-enzyme-inhibitors | Cardiac and Cardiovascular Systems | randomized intervention trial | quality-of-care | elderly-patients | cardiac-insufficiency | national-survey | medical-treatment | ventricular systolic dysfunction | general-practice
Journal Article
Circulation: Heart Failure, ISSN 1941-3289, 01/2016, Volume 9, Issue 1
Background The prevalence of pre-diabetes mellitus and its consequences in patients with heart failure and reduced ejection fraction are not known. We... 
heart failure | Clinical trial | diabetes mellitus | prognosis | treatment outcome | clinical trial | CARDIAC & CARDIOVASCULAR SYSTEMS | PREDICTOR | TOLERANCE | HEMOGLOBIN A(1C) | HOSPITALIZATION | INHIBITION | A1C | INSULIN-RESISTANCE | GLUCOSE | DYSFUNCTION | OUTCOMES | Diabetes Mellitus - blood | Single-Blind Method | Prevalence | Prospective Studies | Ventricular Function, Left | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Heart Failure - physiopathology | Aminobutyrates - adverse effects | Male | Heart Failure - blood | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Enalapril - adverse effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Time Factors | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Female | Heart Failure - diagnosis | Diabetes Mellitus - diagnosis | Diabetes Mellitus - mortality | Prediabetic State - epidemiology | Heart Failure - mortality | Prediabetic State - blood | Risk Assessment | Comorbidity | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Biomarkers - blood | Heart Failure - drug therapy | Prediabetic State - mortality | Prediabetic State - diagnosis | Stroke Volume | Disease-Free Survival | Diabetes Mellitus - epidemiology | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Blood Glucose - metabolism | Angiotensin Receptor Antagonists - therapeutic use | Drug Combinations | Angiotensin Receptor Antagonists - adverse effects | 10093 | 10150 | 10094 | Original | glucose | hospitalization | inhibition | Klinisk medicin | dysfunction | Clinical Medicine | a1c | insulin-resistance | hemoglobin a(1c) | Cardiovascular System & Cardiology | predictor | cardiovascular risk | tolerance
Journal Article
European heart journal, ISSN 0195-668X, 2014, Volume 35, Issue 40, pp. 2797 - 2811
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 2016, Volume 133, Issue 11, pp. 1115 - 1124
Heart failure affects ≈5.7 million people in the United States alone. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, and... 
Heart failure | Prescription drugs | Pharmacology | Natriuretic peptides | heart failure | CARDIAC & CARDIOVASCULAR SYSTEMS | ATRIAL-NATRIURETIC-PEPTIDE | HEART-FAILURE | PHARMACODYNAMICS | TRIAL | natriuretic peptides | GROWTH-FACTOR-BETA | PHARMACOKINETICS | prescription drugs | pharmacology | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | LCZ696 | CONVERTING-ENZYME INHIBITOR | ENDOPEPTIDASE INHIBITION | Drug Costs | Prodrugs - administration & dosage | Valsartan - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Tetrazoles - economics | Angiotensin Receptor Antagonists - pharmacology | Heart Failure - physiopathology | Hypertension - drug therapy | Thiazepines - adverse effects | Thiazepines - therapeutic use | Aminobutyrates - therapeutic use | Biphenyl Compounds - metabolism | Biphenyl Compounds - therapeutic use | Enalapril - therapeutic use | Contraindications | Pyridines - adverse effects | Aminobutyrates - pharmacokinetics | Multicenter Studies as Topic | Valsartan - therapeutic use | Tetrazoles - administration & dosage | Female | Aminobutyrates - administration & dosage | Pyridines - therapeutic use | Bradykinin - metabolism | Kidney - drug effects | Enzyme Inhibitors - metabolism | Valsartan - pharmacokinetics | Stroke Volume - drug effects | Aminobutyrates - metabolism | Enzyme Inhibitors - therapeutic use | Heart Failure - drug therapy | Randomized Controlled Trials as Topic | Drug Synergism | Pregnancy | Natriuretic Peptides - physiology | Prodrugs - pharmacokinetics | Abnormalities, Drug-Induced - etiology | Neprilysin - antagonists & inhibitors | Aminobutyrates - economics | Hyperkalemia - chemically induced | Angioedema - chemically induced | Tetrazoles - therapeutic use | Prodrugs - therapeutic use | Angiotensin Receptor Antagonists - therapeutic use | Drug Combinations | Tetrazoles - pharmacokinetics | Care and treatment | Dosage and administration | Analysis | Angiotensin II receptor blockers | natriuretic peptide | drug
Journal Article
Drugs, ISSN 0012-6667, 2004, Volume 64, Issue 15, pp. 1657 - 1670
The US FDA has approved two drugs for the management of intermittent claudication: pentoxifylline and cilostazol. The mechanism of action that provides symptom... 
Cilostazol, therapeutic use | Fibroblast growth factor gene therapy, therapeutic | Prostaglandins, therapeutic use | Naftidrofuryl, therapeutic use | Pentoxifylline, therapeutic use | Arginine, therapeutic use | Policosanol, therapeutic use | Ticlopidine, therapeutic use | Research and development | Buflomedil, therapeutic use | Vascular endothelial growth factor, therapeutic us | Intermittent claudication, treatment | Fibroblast growth factor 2, therapeutic use | Glutathione, therapeutic use | Sulodexide, therapeutic use | Vascular endothelial growth factor gene therapy, t | Ginkgo biloba leaf extract, therapeutic use | Levocarnitine, therapeutic use | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | LONG-TERM | ANTIPLATELET AGENT | DOUBLE-BLIND | CAMP-PHOSPHODIESTERASE INHIBITOR | PHARMACOLOGY & PHARMACY | PROPIONYL-L-CARNITINE | TOXICOLOGY | QUALITY-OF-LIFE | GROWTH-FACTOR | GENE-TRANSFER | PERIPHERAL ARTERIAL-DISEASE | THERAPEUTIC ANGIOGENESIS | Vasodilator Agents - therapeutic use | Humans | Intermittent Claudication - drug therapy | Treatment Outcome | Clinical Trials as Topic | Pentoxifylline - adverse effects | Pentoxifylline - therapeutic use | Animals | Tetrazoles - administration & dosage | Tetrazoles - therapeutic use | Tetrazoles - adverse effects | Vasodilator Agents - adverse effects | Pentoxifylline - administration & dosage | Vasodilator Agents - administration & dosage
Journal Article
European journal of heart failure, ISSN 1388-9842, 2014, Volume 16, Issue 7, pp. 817 - 825
Journal Article